● pepmg Research Desk · Peer-reviewed evidence review
What the research says about bronchogen
A neutral summary of the peer-reviewed literature on bronchogen, a synthetic Ala-Asp-Glu-Leu short peptide bioregulator studied only in animal lung models and in-vitro cell and DNA assays. There are no controlled human trials. Research use only.
Preclinical only — Animal or in-vitro studies only — no controlled human trials. This describes the state of the published literature, not a claim that this compound works, is safe, or is for human use. Research use only.
The short version
- Bronchogen is described in the literature as a synthetic tetrapeptide (reported as Ala-Asp-Glu-Leu, also written Ala-Glu-Asp-Leu), one of the Khavinson-type short peptide bioregulators studied around respiratory tissue [1][5].
- The evidence is entirely preclinical: in rat models of NO2-induced obstructive lung pathology, studies report reduced neutrophilic inflammation, restored bronchial-epithelium structure, and increased secretory IgA and surfactant protein B [1][2].
- In-vitro work, including human bronchial-cell cultures and cell-free DNA assays, reports effects on differentiation markers and DNA binding; there are no controlled human trials of bronchogen, and the work is essentially from a single research group [4][5][6].
- This page reports what the studies measured. It is not medical advice, an efficacy or safety claim, or dosing guidance. Research use only.
What bronchogen is
Bronchogen is characterized in the literature as a synthetic short tetrapeptide, reported with the sequence Ala-Asp-Glu-Leu (and also written Ala-Glu-Asp-Leu in some reports), one of a family of Khavinson-type short peptide bioregulators (cytogens) [1][5]. It is studied in the context of respiratory and bronchial tissue, and organ-culture work reports that these peptides act tissue-specifically toward their source tissue [3].
Bronchogen is a research compound, not an approved medicine. Material sold by third-party research-chemical vendors is offered for laboratory and research use only.
What the research has measured
Preclinical onlyThe evidence for bronchogen is entirely preclinical. In rats with chronic obstructive pulmonary disease modeled by 60-day intermittent exposure to nitrogen dioxide, a course of bronchogen was reported to reduce signs of bronchial-epithelium remodeling (goblet-cell hyperplasia, squamous metaplasia, lymphocytic infiltration, and emphysema) and to restore ciliated cells, alongside increased secretory immunoglobulin A [1]. A companion study in the same model reported decreased neutrophilic inflammation, normalization of the cytokine profile in the bronchoalveolar space, and increased secretory immunoglobulin A and surfactant protein B [2]. These are measured endpoints in a rat lung model, not findings in people.
In-vitro work describes tissue-specific and molecular effects. In organotypic cultures of lung explants from young and old rats, bronchogen at low concentrations was reported to stimulate the appropriate tissue culture relative to control explants [3]. In cultures of human bronchial epithelial cells, bronchogen was reported to tissue-specifically stimulate the differentiation markers Hoxa3 and CXCL12, an effect described as more pronounced in aged (late-passage) cultures [4]. This is in-vitro work on cultured human cells, not administration to people.
A further line of work is molecular. In a differential-scanning-calorimetry assay, bronchogen was reported to act as a DNA-stabilizing agent, increasing the melting temperature of calf-thymus and mouse-liver DNA by about 3.1 degrees within a narrow ratio range [5], and in cultured HeLa cells (a human-derived cell line) fluorescence-labeled bronchogen was observed to interact with defined DNA sequences [6]. These are in-vitro binding observations, not clinical outcomes.
What the trials report on safety and adverse events
Preclinical onlyThere are no controlled human trials of bronchogen, and the abstracts reviewed here contain no human adverse-event data. Nothing in this literature reports rates of side effects in people.
The preclinical abstracts describe measured tissue and molecular changes rather than a formal toxicity profile. In the rat obstructive-lung models, bronchogen was reported to reduce inflammatory and remodeling markers [1][2], and the in-vitro assays describe cell-differentiation and DNA-binding effects [4][5]. These are measured effects in animal and cell models, not a human safety characterization, and the abstracts do not report toxicity testing.
Because the data are preclinical, nothing here should be read as a safety statement for people. Material sold by research-chemical vendors is not a regulated medicine. This is not medical advice; consult a qualified professional and read the studies directly.
How strong is the evidence
The evidence for bronchogen is characterized as preclinical: it consists of animal lung-model studies and in-vitro work (organ culture, human bronchial-cell culture, and cell-free DNA assays), with no controlled human trials of bronchogen as an administered compound and a literature drawn essentially from a single research group [1][2][4][5]. "Preclinical" describes the design and scope of the published studies, not an endorsement, and the scope is narrow: the human-cell findings are in cultured cells, not in people.
Nothing here is dosing, medical, or safety guidance. Read the studies themselves and consult a qualified professional. This page is a map to the evidence, not a recommendation.
Sources · 6
- Modulating Effect of Peptide Therapy on the Morphofunctional State of Bronchial Epithelium in Rats with Obstructive Lung Pathology.
- [ANTIINFLAMMATORY AND REGENERATIVE EFFECT OF PEPTIDE THERAPY IN THE MODEL OF OBSTRUCTIVE LUNG PATHOLOGY].
- [The tissue-specific effect of synthetic peptides-biologic regulators in organotypic tissues culture in young and old rats].
- Peptides tissue-specifically stimulate cell differentiation during their aging.
- Effect of the peptide bronchogen (Ala-Asp-Glu-Leu) on DNA thermostability.
- Penetration of short fluorescence-labeled peptides into the nucleus in HeLa cells and in vitro specific interaction of the peptides with deoxyribooligonucleotides and DNA.
pepmg summarizes the peer-reviewed literature and links to every source — it sells nothing, ships nothing, and gives no medical, dosing, or human-use guidance. Don't just trust this summary: follow any citation to its source and read it yourself. Research use only.